Rezolute announced on November 13 that the open-label Phase 3 upLIFT study of ersodetug in tumor hyperinsulinism has met its primary efficacy endpoint, based on a November 5 interim data evaluation. The company reported that the primary endpoint — the proportion of patients achieving at least a 50% reduction from baseline in glucose infusion rate (GIR), a clinical measure of intravenous glucose dependency — was achieved in the ongoing study. Investigators reported that 13 participants met the responder criterion at the time of the review, and 12 of those also achieved complete discontinuation of IV glucose.
The announcement states that three participants remain in the pivotal period; two of those have not yet met the responder criterion. One participant discontinued the study early to enter home hospice and subsequently died from cancer progression; Rezolute has classified that participant as a non-responder for the primary endpoint. The company expects completed study results and the formal statistical analysis of the primary endpoint by mid-December 2026.
Rezolute’s CEO, Nevan Charles Elam, was quoted describing the results as consistent with outcomes observed in the company’s expanded access program and indicated plans to pursue regulatory discussions with the U.S. Food and Drug Administration in the first quarter of 2027.
The source describes upLIFT as a single-arm, open-label, registrational Phase 3 trial enrolling approximately 16 participants with tumor hyperinsulinism caused by either insulin-secreting islet cell tumors (insulinomas) or non-islet cell tumors (NICTs). The 16 enrolled participants noted in the announcement included four with non-islet cell tumors and 12 with insulinomas. Eligible participants who require continuous IV glucose receive ersodetug 9 mg/kg per week for 8 weeks as add-on therapy to standard of care, according to the sponsor’s description.
Primary and additional endpoints are clearly stated by the sponsor. The primary endpoint is the proportion achieving a ≥50% reduction in GIR from baseline. Secondary or supportive measures described include the number of participants achieving complete discontinuation of GIR and time to discontinuation, time to hospital discharge as applicable, the extent of hypoglycemia events and time in the outpatient setting as measured by self-monitored blood glucose and continuous glucose monitoring, and patient-reported quality of life.
The company reported that ersodetug has been well tolerated to date in the pivotal and extension phases of the study, and that no drug-related safety findings have been attributed to the antibody in the reported data. The source also provides a mechanistic summary: ersodetug is a fully human monoclonal antibody that binds allosterically to the insulin receptor to decrease receptor over-activation by insulin and related substances such as IGF-2, an approach intended to reduce hypoglycemia driven by diverse causes of hyperinsulinism.
On Nov. 9, Spruce Biosciences announced the separation of its CRHX-101 program (formerly SPR-202) into a newly formed, wholly owned subsidiary named Adrenyx Biosciences, which will operate as a dedicated endocrinology company. Spruce framed the Separation as a means to allow each company to pursue distinct strategic paths: Spruce will remain focused on neurological disorders while Adrenyx will concentrate on advancing CRHX-101, designed to selectively neutralize corticotropin-releasing hormone (CRH) as an upstream driver of adrenal androgen excess in classic congenital adrenal hyperplasia (CAH).
Samir Gharib, currently President and CFO of Spruce, will serve as President and CEO of Adrenyx and is expected to continue in his roles at Spruce following the Distribution. The announcement named other initial Adrenyx leadership positions: Kirk Ways, MD, PhD, as Chief Medical Officer; Patrick Gearing, PhD, as Head of Chemistry, Manufacturing and Controls; and Meghan Bowler, PhD, as Project Team Leader. The company said additional board and management appointments will be announced later.
Adrenyx’s near-term development priorities documented in the release include completing IND-enabling nonclinical studies and chemistry, manufacturing and controls activities, filing an Investigational New Drug application with the FDA for CRHX-101, and initiating a clinical program thereafter.
Spruce and Adrenyx entered into a separation and distribution agreement and a transition services agreement effective Nov. 6, 2026. Under those agreements, Spruce contributed assets and liabilities related to the CRHX-101 program to Adrenyx, and agreed to provide specified services to Adrenyx for up to 12 months post-Distribution at cost. The company reported that Spruce’s board had not yet approved the Distribution nor had a record date been set at the time of the announcement.
Financing steps disclosed include a secured convertible note purchase agreement between Adrenyx and an institutional biotechnology investor allowing issuance of notes in an aggregate principal amount of up to $10.0 million. At the initial closing on Nov. 6, 2026, Adrenyx issued $5.0 million aggregate principal amount of the secured convertible promissory notes. The announcement states that Adrenyx is required to use the proceeds to develop and commercialize CRHX-101 and for general corporate purposes; Spruce is not permitted to use those proceeds for its own operations.
Spruce indicated that a private placement of Adrenyx equity securities to institutional investors is expected in connection with the Distribution and that the investor may fund up to $50 million inclusive of the convertible note funding; further details were to be announced at or prior to the private placement closing. The Distribution of Adrenyx shares to Spruce stockholders is expected to occur in the first half of 2027, subject to satisfaction or waiver of customary conditions set forth in the separation and distribution agreement, including Spruce board approval, effectiveness of an Adrenyx SEC registration statement, and Nasdaq listing approval.
Several documented uncertainties remain. Final statistical analyses and the completed upLIFT study results are expected by mid-December 2026 but were not yet released in the source. Rezolute indicated plans to discuss regulatory pathways with FDA in Q1 2027. Spruce’s announcement notes that there can be no assurance that the Distribution, subsequent note issuances, or the private placement will be completed on the anticipated timeline, on anticipated terms, or at all.